Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer (Q38222512)

31 August 2017

title

Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer (English)

1 reference

31 August 2017

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24956256%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Géraldine Perkins

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24956256%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Camilla Pilati

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24956256%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Helene Blons

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24956256%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Geraldine Perkins

1

1 reference

31 August 2017

Camilla Pilati

2

1 reference

31 August 2017

Helene Blons

3

1 reference

31 August 2017

publication date

1 May 2014

1 reference

31 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24956256%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24956256%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24956256%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

1043-1052

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24956256%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

cites work

Cancer statistics, 2010

1 reference

Therapy for metastatic colorectal cancer

21 January 2018

1 reference

Mutations and response to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

The epidermal growth factor receptor pathway: a model for targeted therapy

21 January 2018

1 reference

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.

21 January 2018

1 reference

Comprehensive molecular characterization of human colon and rectal cancer

21 January 2018

1 reference

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.

21 January 2018

1 reference

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer

21 January 2018

1 reference

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

Oncogenic activating mutations are associated with local copy gain

21 January 2018

1 reference

Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine

21 January 2018

1 reference

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

21 January 2018

1 reference

Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells

21 January 2018

1 reference

Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival

21 January 2018

1 reference

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.

21 January 2018

1 reference

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

21 January 2018

The two TORCs and Akt.

1 reference

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

21 January 2018

1 reference

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

21 January 2018

1 reference

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

21 January 2018

1 reference

PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

21 January 2018

1 reference

Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

21 January 2018

1 reference

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.

21 January 2018

1 reference

PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.

21 January 2018

1 reference

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.

21 January 2018

1 reference

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 January 2018

1 reference

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

21 January 2018

1 reference

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

21 January 2018

1 reference

HGF rescues colorectal cancer cells from EGFR inhibition via MET activation

21 January 2018

1 reference

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance

21 January 2018

1 reference

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells

21 January 2018

1 reference

EGFR and cancer prognosis

21 January 2018

1 reference

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer

21 January 2018

1 reference

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

21 January 2018

1 reference

EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis

21 January 2018

1 reference

Somatic mutations of EGFR in colorectal cancers and glioblastomas

21 January 2018

1 reference

Molecular determinants of cetuximab efficacy

21 January 2018

1 reference

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

21 January 2018

1 reference

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

21 January 2018

1 reference

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

21 January 2018

1 reference

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

21 January 2018

1 reference

Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study

21 January 2018

1 reference

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

21 January 2018

1 reference

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

21 January 2018

1 reference

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

21 January 2018

1 reference

Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial

21 January 2018

1 reference

HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome

21 January 2018

1 reference

Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.

21 January 2018

1 reference

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

21 January 2018

1 reference

Monoclonal antibodies for the treatment of cancer

21 January 2018

1 reference

Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

21 January 2018

1 reference

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

21 January 2018

1 reference

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

21 January 2018

1 reference

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.

21 January 2018

1 reference

Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?

21 January 2018

1 reference

Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer.

21 January 2018

1 reference

Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.

21 January 2018

1 reference

KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells

21 January 2018

1 reference

Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade

21 January 2018

1 reference

MicroRNAs targeting EGFR signalling pathway in colorectal cancer.

21 January 2018

1 reference

High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease

21 January 2018

1 reference

Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan

21 January 2018

1 reference

Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab

21 January 2018

1 reference

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

21 January 2018

1 reference

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer

21 January 2018

1 reference

Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway.

21 January 2018

1 reference